SPOP and prostate cancer: Endometrial cancer–associated SPOP mutations preferentially degrade BET proteins, while prostate-cancer–specific SPOP mutation results in impaired degradation of BET proteins, as mutations of SPOP degrons in BRD4 determine whether they bind BET proteins or not, thus influencing BET ubiquitination (Janouskova et al., 2017).